Not a good buy right now for an impatient trader: the chart trend is still decisively bearish (bearish MA stack + worsening MACD), and price is sitting on/just below a key support area (~6.07).
Near-term setup looks more like a volatile “falling knife” than a clean reversal; better odds come after a stabilization/reclaim of the pivot (~6.64) or a catalyst.
Options are extremely elevated IV (pricey) with unusually put-heavy today volume, suggesting near-term caution/hedging despite call-heavy open interest.
Insider selling has ramped materially (negative signal), while hedge funds are neutral and there’s no clear event-driven upside catalyst in the latest news.
Momentum: MACD histogram -0.0562 below zero and negatively expanding → bearish momentum is strengthening.
RSI(6): ~22.96 (oversold/washed-out short-term conditions), which can allow bounces, but by itself is not a confirmed entry.
Key levels: Support S1 ~6.066 (pre-market ~6 is slightly below/at this level); next support S2 ~5.714. Resistance/pivot ~6.635; R1 ~7.204.
Pattern-based odds: modestly positive next day/week, but negative bias over next month (model shows -2.99% next month).
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put/Call OI = 0.17 (call OI dominates), which can read as longer-dated bullish positioning.
Today’s flow: Put/Call volume = 604.0 (604 puts vs 1 call) with volume ~565x the 30D average → very bearish/defensive today.
Volatility: IV30 ~322.88 with IV percentile ~99.2 (extremely elevated) → options imply very large moves; sentiment is tense and event-risk is being priced.
Net takeaway: despite call-heavy OI, the current tape is put-dominated and fear/hedging is elevated—this is not a “calm accumulation” signal.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
would be a major upside catalyst (not present in the provided news, but key to watch).
Neutral/Negative Catalysts
Insider activity: insiders are selling, with selling amount up ~253% over the last month (clear negative sentiment signal).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 11.734M, up ~338.49% YoY (strong top-line growth off a low base).
Profitability: Net income -59.1M (still deeply negative), improved ~16.33% YoY but remains a major overhang.
EPS: -0.85, improved ~14.86% YoY (less negative, but still loss-making).
Gross margin: 100 (as reported), but overall financial picture still reflects a development-stage biotech with heavy cash burn risk implied by large losses.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent Street action (provided): Truist initiated coverage (2025-11-24) with Hold and $10 PT.
Rationale: uncertainty around time-to-market and ultimate market potential for Zele pending more visibility from Phase 2/3 Duravelo-2, with competitive pressure noted (Padcev entrenched).
Wall Street pros: pipeline optionality (BT5528, radiopharma franchise) could create upside if data readouts are strong.
Wall Street cons: near-term contribution from early-stage programs is unlikely; clinical/competitive uncertainty keeps conviction muted (Hold).
Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 20.75 USD with a low forecast of 10 USD and a high forecast of 44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 20.75 USD with a low forecast of 10 USD and a high forecast of 44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 5.310
Low
10
Averages
20.75
High
44
Current: 5.310
Low
10
Averages
20.75
High
44
Truist
Hold
initiated
$10
AI Analysis
2025-11-24
Reason
Truist
Price Target
$10
AI Analysis
2025-11-24
initiated
Hold
Reason
Truist initiated coverage of Bicycle Therapeutics with a Hold rating and $10 price target. The time to market and ultimate market potential remains uncertain for Zele, pending further visibility from the Phase 2/3 Duravelo-2 trial, particularly as Padcev continues to entrench as a widely adopted standard of care, the analyst tells investors in a research note. Truist adds that it sees broader value from Bicycle's pipeline, including BT5528, and the radiopharma franchise, though these programs remain early in development and are unlikely to yield meaningful near-term contribution.
RBC Capital
Leonid Timashev
Outperform -> Sector Perform
downgrade
$27 -> $11
2025-10-31
Reason
RBC Capital
Leonid Timashev
Price Target
$27 -> $11
2025-10-31
downgrade
Outperform -> Sector Perform
Reason
RBC Capital analyst Leonid Timashev last night downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27, following the Q3 report. The company's pipeline programs are taking more time to reach inflection points, the analyst tells investors in a research note. RBC thinks Bicycle's near-term updates may not provide substantial enough data to de-risk its programs and drive share upside. As such, the firm moves to the sidelines pending greater visibility into the path forward for zelenectide and BT5528.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BCYC
